サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739140

線維筋痛症治療の世界市場

Fibromyalgia Treatment

出版日
ページ情報
英文 276 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
線維筋痛症治療の世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 276 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

線維筋痛症治療の世界市場は2030年までに22億米ドルに到達

2024年に19億米ドルと推定される線維筋痛症治療の世界市場は、分析期間2024-2030年にCAGR 2.2%で成長し、2030年には22億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである線維筋痛症治療薬は、CAGR 1.7%を記録し、分析期間終了時には14億米ドルに達すると予測されます。線維筋痛症治療薬セグメントの成長率は、分析期間中CAGR 3.3％と推定されます。

米国市場は5億2,130万米ドルと推定、中国はCAGR4.3％で成長予測

米国の線維筋痛症治療市場は、2024年に5億2,130万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.3%として、2030年までに4億1,330万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.6%と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の線維筋痛症治療市場- 主要動向と促進要因まとめ

なぜ線維筋痛症が世界のヘルスケア界で再注目されているのか？

広範な筋骨格痛、疲労、睡眠障害、認知障害を特徴とする慢性疾患である線維筋痛症は、多角的な治療戦略を必要とする複雑な疾患として認知されつつあります。線維筋痛症は、その自覚症状や他の慢性疼痛症候群との重複から、歴史的に過小診断され、誤解されてきました。しかし、臨床的認知度の向上、患者支援活動、科学的調査により、世界のヘルスケアコミュニティにおけるこの疾患の認知度は著しく高まっています。生活の質や日常生活に深刻な影響を及ぼす症状からの解放を求める患者が増えるにつれ、効果的で個別化された治療に対する需要が高まっています。線維筋痛症が中枢性感作障害-脳と脊髄が痛みのシグナルを異常に処理する-であるという理解が深まりつつあることは、単に痛みを隠すことから、その根底にある神経学的・生化学的経路に対処する方向への転換を促しています。その結果、薬物療法、身体的リハビリテーション、心理的サポート、生活習慣への介入など、治療の幅が広がっています。ヘルスケアシステムは、線維筋痛症ケアを統合した慢性疼痛管理の枠組みを優先し始めており、デジタルヘルスプラットフォームは、遠隔症状モニタリングや個別化ケア経路の新たな機会を生み出しています。このような注目の高まりにより、線維筋痛症は誤解されがちな診断から、治療選択肢が拡大し、世界的に治療が注目される、明確に定義された臨床上の優先事項へと変化しつつあります。

薬物療法の進歩は治療プロトコルをどのように形成しているか？

薬理学的研究の著しい進歩により、線維筋痛症の治療プロトコールが再構築されつつあり、従来の鎮痛薬にとどまらず、より広範な標的治療が含まれるようになってきています。市販の鎮痛薬や非ステロイド性抗炎症薬の線維筋痛症患者への有効性は限られているが、デュロキセチンやミルナシプランなどのセロトニン・ノルエピネフリン再取り込み阻害薬（SNRI）やプレガバリンなどの抗けいれん薬などの中枢作用薬は、疼痛、疲労、睡眠障害の管理に測定可能な成功を示しています。これらの薬剤は、痛みの知覚に関与する神経伝達物質を調節し、線維筋痛症の神経化学的不均衡により適したアプローチを提供します。アミトリプチリンのような三環系抗うつ薬は、睡眠を改善し、筋肉痛を軽減する効果があることから処方され続けているが、副作用のために長期間の使用は制限されることが多いです。開発中の新薬候補は、神経炎症、グルタミン酸シグナル伝達、中枢性感作に関与するその他の経路に対処することを目指しています。さらに、医療用大麻やカンナビノイドを用いた治療法の出現は、特に従来の治療に反応しない患者の間で関心を呼んでいます。低用量ナルトレキソン、ケタミン輸液、サイトカイン経路を標的とする生物製剤を研究する臨床試験も、薬理学的フロンティアを広げています。規制当局の承認と現実のエビデンスにより、これらの治療法への幅広いアクセスが促進される一方、製薬会社は副作用の少ないより優れた製剤に投資しています。個別化医療は、治療反応を予測するためのゲノムやメタボロームのプロファイリングが検討されるなど、広がりを見せています。線維筋痛症に対する薬物療法が進化するにつれ、純粋に身体的なものでなく、神経学的な状態としての痛みに対する理解によって導かれることが多くなり、より的を絞った、効果的な、患者に特化した介入が行われるようになってきています。

線維筋痛症の治療において、非薬物療法や統合療法はどのような役割を果たすのか？

非薬物療法は、薬物のみのアプローチの限界と慢性的で多因子性の疾患であることから、線維筋痛症治療において必要不可欠であり、かつ拡大しつつあります。エビデンスに基づくガイドラインでは、全人的な症状コントロールを達成するために、薬物療法と理学療法、認知行動療法（CBT）、マインドフルネス、段階的運動プログラムを組み合わせることの重要性が強調されています。有酸素運動と筋力トレーニングは、疼痛感受性を低下させ、気分を改善させる効果が実証されており、アクアティックセラピーとヨガは、重度の身体的制限のある患者にとって負担の少ない代替療法です。CBTやアクセプタンス＆コミットメント療法（ACT）などの心理療法は、患者がストレス、破局感、感情的疲労（症状再燃の主な誘因）を管理するのに役立ちます。瞑想、バイオフィードバック、太極拳などの心身介入は、神経系を調整し、生活の質を改善する役割を果たすとして人気を集めています。栄養補助、特に抗炎症食やマグネシウム、ビタミンD、オメガ3脂肪酸の補給も治療レジメンに組み込まれつつあります。アプリベースのコーチングや遠隔CBTプラットフォームなどのデジタル治療法は、十分な治療を受けていない人々のケアへのアクセスを拡大しています。さらに、患者教育プログラムは、期待値を管理し、自己効力感を高め、ヘルスケアの過剰利用を防ぐ上で重要な役割を果たしています。現在、多くの学際的なペインクリニックでは、線維筋痛症に合わせた複合的なプログラムを提供しており、臨床的、行動的、生活習慣的介入を1つのケアモデルのもとに融合させています。このようなアプローチの有効性を裏付けるエビデンスが増えるにつれ、非薬物療法は線維筋痛症治療を補うだけでなく、多くの場合、慢性疼痛管理における臨床医と患者の成功の定義を変えつつあります。

線維筋痛症治療市場の世界的成長の原動力は？

世界の線維筋痛症治療市場の成長は、疫学的動向、アンメット・クリニカル・ニーズ、進化する治療パラダイム、ヘルスケア・イノベーションに関連するいくつかの要因によって牽引されています。その最たるものは、慢性疼痛とストレス関連障害の世界の有病率の増加であり、特に高齢化社会と中年期の女性において線維筋痛症と診断されることが多いです。医療従事者の意識の高まり、より優れた診断ツール、世界保健機関（WHO）などの機関による線維筋痛症の正式な認知が、より早期かつ正確な診断につながっており、ひいては治療対象者の拡大につながっています。さらに、個別化・集学的治療モデルへのシフトは、新たな治療経路を開き、患者の定着率を高めています。神経画像やバイオマーカー同定を含む診断の技術的進歩は、より良い疾患層別化と的を絞った介入を促進しています。薬理学的治療のパイプラインの拡大は、規制当局の承認や線維筋痛症治療薬の保険適用の拡大と相まって、先進国市場や新興国市場において治療へのアクセス性を高めています。さらに、患者アドボカシーやオンラインコミュニティの拡大により、積極的に治療を受け、臨床試験に参加する個人の力が高まっています。特にパンデミック後の遠隔医療やバーチャル疼痛管理プログラムの導入により、内科的治療と心理療法の両方へのアクセスが広がっています。医療技術への投資も、線維筋痛症に特化したAI搭載の疼痛トラッカー、デジタル診断、遠隔治療ツールの開発に拍車をかけています。臨床イノベーション、医療需要の高まり、患者中心のケアモデルを軸とするこれらの促進要因が、線維筋痛症治療市場を世界の持続的成長と治療の成熟に向けて後押ししています。

セグメント

治療タイプ（投薬治療タイプ、治療薬治療タイプ）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（全42件）

  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan plc
  • Amneal Pharmaceuticals LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Axsome Therapeutics Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tonix Pharmaceuticals Holding Corp.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33835

Global Fibromyalgia Treatment Market to Reach US$2.2 Billion by 2030

The global market for Fibromyalgia Treatment estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Fibromyalgia Medications, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Fibromyalgia Therapies segment is estimated at 3.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$521.3 Million While China is Forecast to Grow at 4.3% CAGR

The Fibromyalgia Treatment market in the U.S. is estimated at US$521.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$413.3 Million by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Fibromyalgia Treatment Market - Key Trends & Drivers Summarized

Why Is Fibromyalgia Garnering Renewed Attention in Global Healthcare Circles?

Fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties, is gaining increasing recognition as a complex condition requiring multidimensional treatment strategies. Affecting an estimated 2-4% of the global population-predominantly women-fibromyalgia has historically been underdiagnosed and misunderstood due to its subjective symptoms and overlap with other chronic pain syndromes. However, growing clinical awareness, patient advocacy, and scientific research have significantly elevated the profile of this condition within the global healthcare community. The demand for effective and personalized treatments is rising as more patients seek relief from symptoms that severely affect quality of life and daily functioning. The evolving understanding of fibromyalgia as a central sensitization disorder-where the brain and spinal cord process pain signals abnormally-is prompting a shift away from merely masking pain toward addressing the underlying neurological and biochemical pathways. As a result, the treatment landscape is broadening to include pharmacological therapies, physical rehabilitation, psychological support, and lifestyle interventions. Healthcare systems are beginning to prioritize chronic pain management frameworks that integrate fibromyalgia care, while digital health platforms are creating new opportunities for remote symptom monitoring and personalized care pathways. This heightened attention is transforming fibromyalgia from a misunderstood diagnosis into a well-defined clinical priority with expanding treatment options and global therapeutic focus.

How Are Advancements in Pharmacotherapy Shaping Treatment Protocols?

Significant strides in pharmacological research are reshaping the treatment protocols for fibromyalgia, moving beyond traditional analgesics to include a broader range of targeted therapies. While over-the-counter painkillers and NSAIDs have limited effectiveness in fibromyalgia patients, centrally acting medications-such as serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine and milnacipran, and anticonvulsants such as pregabalin-have shown measurable success in managing pain, fatigue, and sleep disturbances. These medications modulate neurotransmitters involved in pain perception, offering a more tailored approach to fibromyalgia's neurochemical imbalances. Tricyclic antidepressants like amitriptyline continue to be prescribed for their efficacy in improving sleep and reducing muscle pain, although side effects often limit long-term use. Novel drug candidates under development aim to address neuroinflammation, glutamate signaling, and other pathways implicated in central sensitization. Moreover, the emergence of medical cannabis and cannabinoid-based therapies is generating interest, especially among patients unresponsive to conventional treatments. Clinical trials investigating low-dose naltrexone, ketamine infusions, and biologics targeting cytokine pathways are also expanding the pharmacological frontier. Regulatory approvals and real-world evidence are encouraging broader access to these therapies, while pharmaceutical companies are investing in better formulations with fewer side effects. Personalized medicine is gaining ground, with genomic and metabolomic profiling being explored to predict treatment responses. As pharmacotherapy for fibromyalgia evolves, it is increasingly guided by an understanding of pain as a neurological condition rather than purely physical, leading to more targeted, effective, and patient-specific interventions.

What Role Do Non-Pharmacological and Integrative Therapies Play in Fibromyalgia Care?

Non-pharmacological therapies are an essential and expanding part of fibromyalgia treatment, driven by the limitations of drug-only approaches and the chronic, multifactorial nature of the condition. Evidence-based guidelines now emphasize the importance of combining medications with physical therapy, cognitive behavioral therapy (CBT), mindfulness, and graded exercise programs to achieve holistic symptom control. Aerobic exercise and strength training have demonstrated benefits in reducing pain sensitivity and improving mood, while aquatic therapy and yoga offer low-impact alternatives for patients with severe physical limitations. Psychological therapies, including CBT and acceptance and commitment therapy (ACT), help patients manage stress, catastrophizing, and emotional exhaustion-key triggers for symptom flares. Mind-body interventions like meditation, biofeedback, and tai chi are gaining popularity for their role in modulating the nervous system and improving quality of life. Nutritional support, particularly anti-inflammatory diets and supplementation with magnesium, vitamin D, or omega-3 fatty acids, is also being integrated into treatment regimens. Digital therapeutics, including app-based coaching and remote CBT platforms, are expanding access to care in underserved populations. Additionally, patient education programs play a critical role in managing expectations, building self-efficacy, and preventing healthcare overutilization. Many interdisciplinary pain clinics now offer multimodal programs tailored to fibromyalgia, blending clinical, behavioral, and lifestyle interventions under one care model. As evidence grows supporting the effectiveness of these approaches, non-pharmacological treatments are not only supplementing but in many cases leading the charge in fibromyalgia care, reshaping how clinicians and patients define success in chronic pain management.

What’s Driving the Global Growth of the Fibromyalgia Treatment Market?

The growth in the global fibromyalgia treatment market is driven by several factors tied to epidemiological trends, unmet clinical needs, evolving treatment paradigms, and healthcare innovation. Foremost is the increasing global prevalence of chronic pain and stress-related disorders, particularly among aging populations and women in midlife, where fibromyalgia is most commonly diagnosed. Rising awareness among healthcare providers, better diagnostic tools, and the formal recognition of fibromyalgia by institutions like the World Health Organization (WHO) are leading to earlier and more accurate diagnoses, which in turn expand the treated population. Additionally, the shift toward personalized and multidisciplinary care models is opening new therapeutic pathways and increasing patient retention. Technological advancements in diagnostics, including neuroimaging and biomarker identification, are facilitating better disease stratification and targeted interventions. The expanding pipeline of pharmacological treatments, coupled with regulatory approvals and growing insurance coverage for fibromyalgia medications, is enhancing treatment accessibility across developed and emerging markets. Moreover, patient advocacy and growing online communities are empowering individuals to seek care proactively and participate in clinical trials. The adoption of telemedicine and virtual pain management programs-particularly post-pandemic-has widened access to both medical and psychological therapies. Healthtech investments are also fueling the development of AI-powered pain trackers, digital diagnostics, and remote therapeutic tools tailored to fibromyalgia. These drivers, anchored in clinical innovation, rising healthcare demand, and patient-centered care models, are collectively propelling the fibromyalgia treatment market toward sustained global growth and therapeutic maturity.

SCOPE OF STUDY:

The report analyzes the Fibromyalgia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Medications Treatment Type, Therapies Treatment Type); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • AbbVie Inc.
  • Allergan plc
  • Amneal Pharmaceuticals LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Axsome Therapeutics Inc.
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tonix Pharmaceuticals Holding Corp.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Fibromyalgia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Chronic Pain Disorders Propels Growth in the Fibromyalgia Treatment Market
    • Increased Awareness and Diagnosis of Fibromyalgia Expands the Addressable Market for Therapeutic Interventions
    • Shift Toward Multimodal Treatment Approaches Throws the Spotlight on Combination Drug and Non-Drug Therapies
    • Advancements in CNS-Acting Medications Strengthen the Business Case for Targeted Pharmacological Solutions
    • Growing Demand for Personalized Pain Management Drives Innovation in Patient-Centric Fibromyalgia Care Plans
    • Expansion of Off-Label Use of Antidepressants and Anticonvulsants Sustains Market Momentum
    • Integration of Cognitive Behavioral Therapy (CBT) and Mind-Body Techniques Propels Adoption of Holistic Treatment Models
    • Rise in Medical Cannabis and Cannabinoid Research Generates Opportunities for Alternative Therapies
    • Digital Health Tools and Remote Monitoring Technologies Throw the Spotlight on Symptom Tracking and Self-Management
    • Increased Focus on Quality of Life and Functional Outcomes Supports Growth of Complementary Therapies Like Acupuncture and Physical Therapy
    • Pharmaceutical R&D in Novel Pain Pathway Modulators Accelerates Development of Mechanism-Based Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Fibromyalgia Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Fibromyalgia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Fibromyalgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medications Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medications Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Medications Treatment Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Therapies Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Therapies Treatment Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Therapies Treatment Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Fibromyalgia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Fibromyalgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Fibromyalgia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Fibromyalgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Fibromyalgia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Fibromyalgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Fibromyalgia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Fibromyalgia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Fibromyalgia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Fibromyalgia Treatment by Treatment Type - Medications Treatment Type and Therapies Treatment Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Fibromyalgia Treatment by Treatment Type - Percentage Breakdown of Value Sales for Medications Treatment Type and Therapies Treatment Type for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Fibromyalgia Treatment by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Fibromyalgia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION